Number of the records: 1
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours
- 1.
SYSNO ASEP 0092894 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours Title CpG oligonukleotidy jsou účinné při terapii minimální zbytkové nádorové choroby MHC I negativních myších nádorů asociovaných s HPV16 po chemoterapii nebo jejich chirurgickém dstranění Author(s) Reiniš, Milan (UMG-J) RID
Šímová, Jana (UMG-J) RID
Indrová, Marie (UMG-J) RID
Bieblová, Jana (UMG-J)
Bubeník, Jan (UMG-J)Source Title International Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
Roč. 30, č. 5 (2007), s. 1247-1251Number of pages 5 s. Language eng - English Country GR - Greece Keywords HPV16 ; minimal residual tumour disease ; CpG oligonucleotides Subject RIV EB - Genetics ; Molecular Biology R&D Projects GA301/04/0492 GA ČR - Czech Science Foundation (CSF) GA301/06/0774 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50520514 - UMG-J (2005-2011) Annotation Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2008
Number of the records: 1